Product Description
AdAPT-001, a type 5 adenovirus, which carries a TGF-beta trap transgene that neutralizes the immunosuppressive cytokine, TGF-beta, has been shown in an immunocompetent mouse model to eradicate both locally injected and non-injected tumors. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/34765319/)
Mechanisms of Action: TGFb Inhibitor
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Injection
FDA Designation: Fast Track - Sarcoma *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: EpicentRx, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Chondrosarcoma|Soft Tissue Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04673942 |
BETA-PRIME | P2 |
Recruiting |
Soft Tissue Cancer|Chondrosarcoma |
2025-12-01 |
38% |
2024-05-10 |
Primary Endpoints |